Skip to main content
NCBI home page
Journal of the National Medical Association logoLink to Journal of the National Medical Association
. 2002 Dec;94(12):1077–1086.

Pharmacy assistance programs in a community health center setting.

Maxsimo C Torres 1, Debra Herman 1, Seferino Montano 1, Leah Love 1
PMCID: PMC2568413  PMID: 12510707

Abstract

Prescription drug costs represent the fastest growing item in health care and are a driving force in rapidly increasing health care costs. Community health centers serve an indigent population with limited access to pharmaceuticals. Pharmaceutical companies sponsor patient assistance programs. These pharmacy assistance programs can be developed to facilitate the provision of needed pharmaceuticals to this vulnerable population. La Casa de Buena Salud is a rural community health center in eastern New Mexico, which has provided access to a substantial amount of pharmaceuticals to indigent patients through patient assistance programs. Cost savings potential are considerable for a community health center and for patients when a pharmacy assistance program is organized efficiently and employed systematically. Secondary benefits are derived from the entire medical community. While some community health centers currently make effective use of pharmaceutical company-sponsored pharmacy assistance programs, a comprehensive, long-term approach at a national level may be required.

Full text

PDF
1077

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Buchanan Robert J. Medicaid managed care and coverage of prescription medications. Am J Public Health. 2002 Aug;92(8):1238–1243. doi: 10.2105/ajph.92.8.1238. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Chisholm M. A., Reinhardt B. O., Vollenweider L. J., Kendrick B. D., DiPiro J. T. Medication assistance programs for uninsured and indigent patients. Am J Health Syst Pharm. 2000 Jun 15;57(12):1131–1136. [PubMed] [Google Scholar]
  3. Nykamp D., Ruggles D. Impact of an indigent care program on use of resources: experiences at one hospital. Pharmacotherapy. 2000 Feb;20(2):217–220. doi: 10.1592/phco.20.3.217.34781. [DOI] [PubMed] [Google Scholar]
  4. Paris W., Dunham S., Sebastian A., Jacobs C., Nour B. Medication nonadherence and its relation to financial restriction. J Transpl Coord. 1999 Sep;9(3):149–152. doi: 10.7182/prtr.1.9.3.j28354x695735514. [DOI] [PubMed] [Google Scholar]
  5. Schneeweiss Sebastian, Walker Alexander M., Glynn Robert J., Maclure Malcolm, Dormuth Colin, Soumerai Stephen B. Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors. N Engl J Med. 2002 Mar 14;346(11):822–829. doi: 10.1056/NEJMsa003087. [DOI] [PubMed] [Google Scholar]
  6. Steinbrook Robert. The prescription-drug problem. N Engl J Med. 2002 Mar 14;346(11):790–790. doi: 10.1056/NEJM200203143461102. [DOI] [PubMed] [Google Scholar]
  7. Van Diepen L. R. Pharmaceutical manufacturer assistance programs for indigent patients: solution or symptom? Am J Health Syst Pharm. 2001 Jan 15;58(2):162–163. doi: 10.1093/ajhp/58.2.162. [DOI] [PubMed] [Google Scholar]
  8. Weiner S., Dischler J., Horvitz C. Beyond pharmaceutical manufacturer assistance: broadening the scope of an indigent drug program. Am J Health Syst Pharm. 2001 Jan 15;58(2):146–150. doi: 10.1093/ajhp/58.2.146. [DOI] [PubMed] [Google Scholar]

Articles from Journal of the National Medical Association are provided here courtesy of National Medical Association

RESOURCES